Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Invested Capital: 2016-2025

Historic Invested Capital for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $313.7 million.

  • Rocket Pharmaceuticals' Invested Capital fell 4.88% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 4.88%. This contributed to the annual value of $463.2 million for FY2024, which is 5.96% down from last year.
  • Rocket Pharmaceuticals' Invested Capital amounted to $313.7 million in Q3 2025, which was down 11.45% from $354.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Invested Capital's 5-year high stood at $541.1 million during Q3 2023, with a 5-year trough of $313.7 million in Q3 2025.
  • In the last 3 years, Rocket Pharmaceuticals' Invested Capital had a median value of $412.1 million in 2025 and averaged $417.7 million.
  • In the last 5 years, Rocket Pharmaceuticals' Invested Capital surged by 100.82% in 2021 and then crashed by 39.05% in 2024.
  • Rocket Pharmaceuticals' Invested Capital (Quarterly) stood at $454.7 million in 2021, then rose by 7.69% to $489.7 million in 2022, then grew by 0.59% to $492.6 million in 2023, then decreased by 5.96% to $463.2 million in 2024, then decreased by 4.88% to $313.7 million in 2025.
  • Its Invested Capital stands at $313.7 million for Q3 2025, versus $354.2 million for Q2 2025 and $412.1 million for Q1 2025.